Oragenics, a nutraceutical company focused on oral care probiotics for humans and companion pets, today announced the completion of an independently conducted clinical trial for EvorKids®, the company’s branded product designed to support oral health in children ages 3 to 11.
The randomized, double-blind study enrolled 60 six- to 12-year old children prone to tooth decay/cavity (caries). The study evaluated baseline levels of key oral bacterial species mutans Streptococci and Lactobacilli, which are recognized as risk factors to the development of caries. After four weeks of treatment of EvorKids®, Oragenis reports that results show a statistically significant decrease from baseline of the levels with no adverse events reported during the trial.
Mark Cannon, DDS, the lead author of this independent study, is a faculty member at Northwestern University, an attending physician at Children’s Memorial Hospital, Chicago, and a diplomate of the American Board of Pediatric Dentistry. Dr. Cannon said the clinical study demonstrates that caries-prone children may benefit from the use of probiotics as part of a daily dental hygiene regimen.
John N. Bonfiglio, Ph.D., CEO of Oragenics, noted the results impact on the company itself.
“Oragenics is encouraged by the results of this first independent study in children employing the company’s proprietary blend of oral care probiotics,” Dr. Bonfiglio stated in the press release. “These data agree with previous results obtained from animal and adult human studies conducted by both Oragenics and independent investigators such as Dr. Cannon, and reinforce the claim that the active ingredient in EvoraKids, ProBiora3®, promotes oral health by helping to maintain a naturally balanced oral microflora.”
Oragenics said the trial details and results will be presented on March 21, 2012, at the American Association for Dental Research (AADR) Annual Meeting in Tampa, Fla. The study is titled “DNA-PCR and CRT Results in Children after Probiotic Use,” as part of an entire scientific session of clinical studies related to dental cariology.
For more information visit www.iadr.org
About MissionIR
MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.
Sign up for “The Mission Report” at www.MissionIR.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html
